Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue with 94% sequence homology to native human GLP-1. As a GLP-1 receptor agonist, it selectively binds to and activates the GLP-1 receptor, a key regulator of glucose metabolism. Semaglutide mimics the physiological effects of GLP-1, stimulating insulin secretion and inhibiting glucagon release in a glucose-dependent manner. Its long half-life is attributed to albumin binding, which enhances metabolic stability, reduces renal clearance, and protects the molecule from degradation by the DPP-4 enzyme.
Clinically, semaglutide is approved for the treatment of type 2 diabetes and is administered via subcutaneous injection. It helps regulate blood glucose by promoting insulin secretion during hyperglycemia and suppressing glucagon secretion, effectively lowering blood sugar levels. Additionally, semaglutide delays gastric emptying in the early postprandial phase, further supporting glycemic control. Its use improves patient outcomes and supports metabolic regulation in individuals with impaired glucose tolerance.
In research and clinical monitoring, semaglutide therapy is often guided by therapeutic drug monitoring (TDM), which evaluates drug concentrations at designated intervals. TDM helps optimize dosing regimens by assessing efficacy, compliance, potential drug-drug interactions, and toxicity risk. This is especially relevant in patients with variable metabolic responses or comorbidities, enabling more precise and individualized diabetes management.
This product is manufactured in Turkey by Matriks Biotek.